To inform about the FDA approval of zanidatamab-hrii for treating HER2-positive gastroesophageal adenocarcinoma.
Approach:
Treatment Options: Zanidatamab-hrii is approved in combination with tislelizumab-jsgr and chemotherapy for patients with HER2-positive tumors that are immunohistochemistry 3-positive or 2-positive and in situ hybridization-positive.
Clinical Trial: The approval was based on the ongoing phase 3 HERIZON-GEA-01 trial.
Key Findings:
Zanidatamab-containing regimens reduced the risk of disease progression or death by 35% compared to trastuzumab plus chemotherapy.
Median progression-free survival was 12.4 months with zanidatamab vs 8.1 months with trastuzumab.
In the overall HER2-positive population, zanidatamab plus tislelizumab and chemotherapy reduced the risk of death by 28%.
Median overall survival was 26.4 months with zanidatamab vs 19.2 months with trastuzumab.
Diarrhea was the most common adverse reaction reported.
Interpretation:
Progression-free and overall survival findings were consistent across prespecified subgroups.
Limitations:
Serious adverse reactions occurred in 59% of patients receiving zanidatamab with tislelizumab and chemotherapy.
Permanent discontinuation due to adverse reactions occurred in 13% of patients receiving zanidatamab with tislelizumab.
Conclusion:
Zanidatamab-hrii offers new first-line treatment options for patients with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.
Researchers reported that an artificial intelligence workflow maintained high interpretive accuracy while reducing urine drug test sign-out time in a supervised clinical laboratory setting.
